Treatment of patients (pts) with chemotherapy-refractory chronic lymphocytic leukemia (CLL) with nonmyeloablative (NM) conditioning and hematopoietic cell transplantation (HCT) from HLA-matched related (MRD) or unrelated donors (URD)
Mohamed L. Sorror(University of Washington Medical Center), David G. Maloney(Fred Hutch Cancer Center), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Dietger Niederwieser(Leipzig University of Applied Sciences), Barry E. Storer(City Of Hope National Medical Center), Ute Hegenbart(Heidelberg University), Brenda M. Sandmaier(University of Washington), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Peter A. McSweeney(Mesoblast (United States)), E.D. Agura, Karl G. Blume(City Of Hope National Medical Center), Michael B. Maris(Colorado Blood Cancer Institute), T Chauncey, Michelle Little(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), José F. Leis(Mayo Clinic), Michael A. Pulsipher(Primary Children's Hospital), James C. Wade(Medizinische Hochschule Hannover), M. Jain-Stuart(Palo Alto University)
Cited by 5
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k